Diabetic Foot Ulcer Therapeutics - A Pipeline Analysis Report| Technavio
May. 16, 2018
LONDON--(BUSINESS WIRE)--May 16, 2018-- has announced their latest pipeline analysis report on the market. The report comprises an exhaustive analysis of the pipeline molecules under investigation within the defined data collection period to treat diabetic foot ulcer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180516005599/en/
Technavio has published a new pipeline analysis report on the global diabetic foot ulcer therapeutics market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed breakdown of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are anticipated to play an important role in the growth of the market in the coming years.
Diabetic foot ulcer therapeutics- market overview and forecast
Insulin allows the blood sugar (glucose) to enter the cells, where it can be utilized for energy. As the body is unable to make enough insulin or utilize the available insulin effectively, the level of the blood sugar rises. High level of glucose levels can result in blindness, heart disease, stroke, kidney failure, and amputation of toes, feet, or legs. As per a research, one-fourth of the diabetes patients have the risk of foot ulcer development during a lifetime. Foot ulcers develop because of the composite interaction between three entities, including ischemia, neuropathy, and infection.
According to a senior analyst at Technavio for , “Ischemia is usually attributed to the peripheral arterial disease that is remarkably frequent in diabetes and results in the poor supply of nutrients to the peripheral tissue. Neuropathy leads to the absence of protective sensation in patients due to which trauma such as induced stepping on a sharp object may not get recognized resulting in the continued destruction of the tissue. Besides, it leads to multiple deformities of the foot, resulting in an abnormal distribution of the focal pressure on foot’s plantar aspect.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Diabetic foot ulcer therapeutics - segmentation analysis
This market research report segments the market based on therapies employed (monotherapy, combination therapy, and unknown), RoA (topical, intramuscular, subcutaneous, intralesional, injectable, oral, and unknown), therapeutic modalities (small molecule, biological, peptide, and unknown), targets for drugs under development (unknown, HIF prolyl hydroxylase, eschar and PDE 5, fibroblast growth factor, interleukin, AMPK, ATP- binding cassette sub-family b member 5 protein, beta-1 adrenergic receptor, cathecilidin, cell membrane, DNA topoisomerase, granzyme B inhibitor, hepatocyte growth factor, platelet-derived growth factor, vascular endothelial growth factor, vascular growth factors, cytokines, immune cells, and zonola occludens (ZO – 1)), and recruitment status (recruiting, completed, active not recruiting, not yet recruiting, ongoing, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, 24 molecules belong to this group, which includes four molecules in Phase III, eight in Phase II, five molecules in Phase I/II, three molecules in Phase I, and four molecules in pre-clinical stage.
Biologicals are biomolecules or macromolecules that are usually called as biological materials. They include large macromolecules such as carbohydrates, nucleic acids, and proteins. Around 38% of the molecules in the current pipeline belong to this group.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180516005599/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH DIABETES
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/16/2018 06:37 AM/DISC: 05/16/2018 06:37 AM